Home > Boards > US Listed > Biotechs > Calithera Biosciences, Inc. (CALA)

Compositions and Methods for Inhibiting Arginase Activity

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Sikmarson Member Profile
 
Followed By 2
Posts 81
Boards Moderated 0
Alias Born 06/23/14
160x600 placeholder
Current Report Filing (8-k) Edgar (US Regulatory) - 6/3/2019 4:09:58 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 6/3/2019 4:09:55 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 6/3/2019 4:09:24 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 6/3/2019 4:07:58 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 6/3/2019 4:07:44 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 6/3/2019 4:07:32 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 6/3/2019 4:07:31 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 6/3/2019 4:06:49 PM
Biotechs That Successfully Combat Cancer Could See Blockbuster Returns NetworkNewsWire - 5/29/2019 8:45:00 AM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 5/24/2019 4:07:22 PM
Amended Statement of Ownership (sc 13g/a) Edgar (US Regulatory) - 5/10/2019 1:21:06 PM
Quarterly Report (10-q) Edgar (US Regulatory) - 5/9/2019 5:07:20 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 5/9/2019 4:56:00 PM
Calithera Biosciences Reports First Quarter 2019 Financial Results and Recent Highlights  GlobeNewswire Inc. - 5/9/2019 4:06:00 PM
Calithera Biosciences to Report First Quarter 2019 Financial Results on Thursday, May 9, 2019 GlobeNewswire Inc. - 5/3/2019 7:05:00 AM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 4/17/2019 4:07:07 PM
Additional Proxy Soliciting Materials (definitive) (defa14a) Edgar (US Regulatory) - 4/5/2019 4:13:37 PM
Proxy Statement (definitive) (def 14a) Edgar (US Regulatory) - 4/5/2019 4:08:32 PM
Calithera Biosciences Presents New Preclinical Data for CB-708 at AACR Annual Meeting 2019 GlobeNewswire Inc. - 4/2/2019 7:05:00 AM
Calithera Biosciences Initiates Phase 1/2 Trial of Telaglenastat in Combination with the PARP Inhibitor Talazoparib GlobeNewswire Inc. - 3/26/2019 7:05:00 AM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 3/19/2019 4:07:25 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 3/13/2019 4:12:05 PM
Securities Registration: Employee Benefit Plan (s-8) Edgar (US Regulatory) - 3/7/2019 4:53:02 PM
Annual Report (10-k) Edgar (US Regulatory) - 3/7/2019 4:50:15 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 3/7/2019 4:14:38 PM
Sikmarson   Friday, 12/30/16 09:37:55 AM
Re: None
Post # of 184 
Compositions and Methods for Inhibiting Arginase Activity
Publication Number:20160375044
Publication Date: 29.12.2016

link patenscope

COMPOSITIONS AND METHODS FOR INHIBITING ARGINASE ACTIVITY
Pub. No.: WO/2016/210106
Publication Date: 29.12.2016

link patentscope

HETEROCYCLIC INHIBITORS OF GLUTAMINASE
Publication Number: 10201607685S
Publication Date: 29.11.2016

link patentscope







Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist